CO5251425A1 - METHOD AND COMPOSITIONS TO ADMINISTER TAXANS ORALLY TO HUMAN PATIENTS - Google Patents
METHOD AND COMPOSITIONS TO ADMINISTER TAXANS ORALLY TO HUMAN PATIENTSInfo
- Publication number
- CO5251425A1 CO5251425A1 CO00082131A CO00082131A CO5251425A1 CO 5251425 A1 CO5251425 A1 CO 5251425A1 CO 00082131 A CO00082131 A CO 00082131A CO 00082131 A CO00082131 A CO 00082131A CO 5251425 A1 CO5251425 A1 CO 5251425A1
- Authority
- CO
- Colombia
- Prior art keywords
- taxane
- human patients
- administered
- oral
- orally
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 229940123237 Taxane Drugs 0.000 abstract 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 2
- 108010036949 Cyclosporine Proteins 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 2
- 229960001265 ciclosporin Drugs 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229930105110 Cyclosporin A Natural products 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229930182912 cyclosporin Natural products 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 238000009101 premedication Methods 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Agentes antineoplásticos de taxano que hasta ahora han exhibido pobre o ninguna biodisponibilidad oral, se administran oralmente a pacientes humanos que sufren de condiciones de enfermedad que responden al taxano y se hace suficientemente biodisponible para alcanzar niveles sanguíneos terapéuticos. En una modalidad preferida, el taxano, preferiblemente paclitaxel, se co-administra al paciente con un agente mejorador de ciclosporina oral, preferiblemente ciclosporina A. Por un método preferido, se administra una dosis de mejorador oral aproximadamente 0.5-72 horas antes del taxano y una segunda dosis del mejorador y se administra inmediatamente antes, junto con o inmediatamente después del taxano. También se provee un método para tratar pacientes humanos que sufren de condiciones de enfermedad con respuesta al taxano, así como un método para proveer tal tratamiento a la vez que se previene o reduce la hipersensibilidad y las reacciones alérgicas sin necesidad de pre-medicación.Taxane antineoplastic agents that have so far exhibited poor or no oral bioavailability, are administered orally to human patients suffering from disease conditions that respond to taxane and becomes bioavailable enough to reach therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporine enhancing agent, preferably cyclosporin A. By a preferred method, a dose of oral improver is administered approximately 0.5-72 hours before the taxane and a second dose of the improver and is administered immediately before, together with or immediately after the taxane. A method is also provided to treat human patients suffering from disease conditions with response to taxane, as well as a method to provide such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16231099P | 1999-10-27 | 1999-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5251425A1 true CO5251425A1 (en) | 2003-02-28 |
Family
ID=22585092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00082131A CO5251425A1 (en) | 1999-10-27 | 2000-10-27 | METHOD AND COMPOSITIONS TO ADMINISTER TAXANS ORALLY TO HUMAN PATIENTS |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1225956A1 (en) |
| JP (1) | JP2003512443A (en) |
| KR (1) | KR20030019296A (en) |
| CN (1) | CN1450923A (en) |
| AU (1) | AU1104201A (en) |
| BR (1) | BR0015149A (en) |
| CA (1) | CA2389583A1 (en) |
| CO (1) | CO5251425A1 (en) |
| CZ (1) | CZ20021484A3 (en) |
| HU (1) | HUP0203303A3 (en) |
| IL (1) | IL149360A0 (en) |
| MX (1) | MXPA02004164A (en) |
| NO (1) | NO20022008L (en) |
| PL (1) | PL354777A1 (en) |
| RU (1) | RU2002113659A (en) |
| SK (1) | SK5822002A3 (en) |
| WO (1) | WO2001030448A1 (en) |
| ZA (1) | ZA200203358B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750246B1 (en) | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
| WO2002043765A2 (en) | 2000-11-28 | 2002-06-06 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
| US20040092428A1 (en) * | 2001-11-27 | 2004-05-13 | Hongming Chen | Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof |
| EP1569620A4 (en) * | 2002-10-30 | 2006-03-22 | Spherics Inc | Nanoparticulate bioactive agents |
| US7659310B2 (en) | 2004-04-27 | 2010-02-09 | Formatech, Inc. | Methods of enhancing solubility of agents |
| US7345093B2 (en) | 2004-04-27 | 2008-03-18 | Formatech, Inc. | Methods of enhancing solubility of compounds |
| PE20060416A1 (en) * | 2004-08-03 | 2006-06-09 | Novartis Ag | COMPOSITION OF RENIN INHIBITORS AND EFFUSION PROTEIN INHIBITORS |
| CN101513395B (en) * | 2008-02-20 | 2011-01-12 | 单宝华 | Taxol double-layer soft capsule oral preparation medicament |
| US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
| US8591942B2 (en) | 2009-09-23 | 2013-11-26 | Indu JAVERI | Methods for the preparation of liposomes comprising docetaxel |
| MX341082B (en) | 2010-05-03 | 2016-08-08 | Teikoku Pharma Usa Inc | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same. |
| JO3685B1 (en) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | Non-aqueous taxane nanodispersion formulations and methods of using the same |
| JO3737B1 (en) * | 2015-07-21 | 2021-01-31 | Athenex Therapeutics Ltd | Therapeutic combinations of orally administered paclitaxel and a P-gp inhibitor for the treatment of cancer |
| EP4059497A1 (en) * | 2021-03-17 | 2022-09-21 | Dompé farmaceutici S.p.a. | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
| WO2022195017A1 (en) * | 2021-03-17 | 2022-09-22 | Dompe' Farmaceutici Spa | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| WO1997027855A1 (en) * | 1996-01-31 | 1997-08-07 | Bristol-Myers Squibb Company | A method of making pharmaceutically active taxanes orally bioavailable |
| AU3486297A (en) * | 1996-06-17 | 1998-01-07 | Eli Lilly And Company | Drug resistance and multidrug resistance modulators |
| PL337064A1 (en) * | 1997-05-27 | 2000-07-31 | Baker Norton Pharma | Method of and compositions for orally administering taxanes to human beings |
| GB9718903D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| KR100661879B1 (en) * | 1998-04-01 | 2006-12-27 | 스키에파마 캐나다 인코포레이티드 | Anticancer composition |
| HK1045646A1 (en) * | 1999-05-21 | 2002-12-06 | Abraxis Bioscience, Llc | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
-
2000
- 2000-10-27 JP JP2001532859A patent/JP2003512443A/en active Pending
- 2000-10-27 WO PCT/US2000/029633 patent/WO2001030448A1/en not_active Ceased
- 2000-10-27 AU AU11042/01A patent/AU1104201A/en not_active Abandoned
- 2000-10-27 SK SK582-2002A patent/SK5822002A3/en unknown
- 2000-10-27 RU RU2002113659/15A patent/RU2002113659A/en not_active Application Discontinuation
- 2000-10-27 CO CO00082131A patent/CO5251425A1/en not_active Application Discontinuation
- 2000-10-27 IL IL14936000A patent/IL149360A0/en unknown
- 2000-10-27 CN CN00815924A patent/CN1450923A/en active Pending
- 2000-10-27 CZ CZ20021484A patent/CZ20021484A3/en unknown
- 2000-10-27 CA CA002389583A patent/CA2389583A1/en not_active Abandoned
- 2000-10-27 PL PL00354777A patent/PL354777A1/en not_active Application Discontinuation
- 2000-10-27 HU HU0203303A patent/HUP0203303A3/en unknown
- 2000-10-27 EP EP00972373A patent/EP1225956A1/en not_active Withdrawn
- 2000-10-27 KR KR1020027005396A patent/KR20030019296A/en not_active Withdrawn
- 2000-10-27 BR BR0015149-1A patent/BR0015149A/en not_active IP Right Cessation
- 2000-10-27 MX MXPA02004164A patent/MXPA02004164A/en unknown
-
2002
- 2002-04-26 ZA ZA200203358A patent/ZA200203358B/en unknown
- 2002-04-26 NO NO20022008A patent/NO20022008L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2389583A1 (en) | 2001-05-03 |
| SK5822002A3 (en) | 2003-01-09 |
| PL354777A1 (en) | 2004-02-23 |
| RU2002113659A (en) | 2004-01-27 |
| KR20030019296A (en) | 2003-03-06 |
| CN1450923A (en) | 2003-10-22 |
| CZ20021484A3 (en) | 2003-12-17 |
| IL149360A0 (en) | 2002-11-10 |
| HUP0203303A3 (en) | 2005-01-28 |
| HUP0203303A2 (en) | 2003-02-28 |
| WO2001030448A1 (en) | 2001-05-03 |
| JP2003512443A (en) | 2003-04-02 |
| NO20022008D0 (en) | 2002-04-26 |
| MXPA02004164A (en) | 2002-10-17 |
| EP1225956A1 (en) | 2002-07-31 |
| NO20022008L (en) | 2002-06-19 |
| ZA200203358B (en) | 2003-04-29 |
| AU1104201A (en) | 2001-05-08 |
| BR0015149A (en) | 2002-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5251425A1 (en) | METHOD AND COMPOSITIONS TO ADMINISTER TAXANS ORALLY TO HUMAN PATIENTS | |
| NO20014519D0 (en) | Apomorphine and Sildenafil Preparation | |
| MXPA05006940A (en) | Therapeutic formulations for the treatment of beta-amyloid related diseases. | |
| NO20014842L (en) | Docet shaft in combination with rhuMAb HER2 for the treatment of cancer | |
| BR9809694A (en) | Process and composition for administering taxanes orally to human patients | |
| DE50203456D1 (en) | DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SUCH COMPOUNDS | |
| JP2021502392A5 (en) | ||
| RU2007138867A (en) | TRANS-CLOMIPHENE DOSAGE MODES | |
| RU2007119545A (en) | PEGLIATED LIPOSOMAL DOXORUBICIN IN COMBINATION WITH ECTEINASCIDIN 743 (ECTEINESCIDIN 743) | |
| BRPI0414518A (en) | pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d and parathyroid hormone derivatives | |
| AR045263A1 (en) | METHOD, KIT AND PHARMACEUTICAL COMPOSITION TO TREAT VIRAL INFECTIONS | |
| RU2005131578A (en) | APLIDINE FOR TREATMENT OF MULTIPLE MYELOMA | |
| IL163091A (en) | Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction | |
| WO2001080895A3 (en) | Methods and compositions for the treatment of cardiac indications | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| PT1251850E (en) | USE OF A PREPARATION OF COMBINATION IN CANCER THERAPY | |
| CA2368352A1 (en) | Method for treating neurodegeneration | |
| TW200501967A (en) | Nemorubicin for use in the preparation of a medicament for liver disease | |
| RU2003124971A (en) | METHOD FOR TREATING PATIENTS WITH NEUROTIC AND SOMATOFORM DISORDERS | |
| NZ516026A (en) | Oral administration of taxanes to human patients using cyclosporins as bioavailability-enhancing agents | |
| RU2002113978A (en) | A method of stimulating motor activity of the intestine | |
| Susman | Relapsed Mantle Cell Lymphoma: Thalidomide Adds to Rituximab's Potency | |
| DK1265629T3 (en) | Use of growth hormone in low dose | |
| Kamimura et al. | Drug therapy for depression in Japan | |
| RU2006138043A (en) | METHOD FOR TREATING A STROKE USING DEFIBRINOGENIZING AGENTS TO ACHIEVE THE SPECIFIC CHARACTER OF DEFIBRINOGENIZATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |